{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "GOLD_22 ", "age_group": "51_plus", "agreed": true, "close_date_time": "2021-10-26 11:50:55", "close_timestamp": 1637927455711, "created": "26/11/2021 11:50:57", "department": "Computing", "disability": true, "ease": 1, "environment": "production", "experiment_date_datepicker": "2021-11-26", "gender": "male", "id": "9d44d9e8-9c2b-4b8c-8dd6-48bcce735e01", "open_date_time": "2021-10-26 11:45:40", "open_timestamp": 1637927140457, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "Antiviral research reported by Dr Kylie Wagstaff investigate Ivermectin and found that it can kill COVID-19 within 48 hrs", "task_condition": "viz", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "post_graduate_phd", "time_taken_in_seconds": 315254, "what": "Drug, Ivermectin, study, treatment viruses", "when_happened": "few_years_ago", "where_location": "Monash University", "who": "Dr Kylie Wagstaff", "why": "The drug kills covid"}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_22 ", "age_group": "51_plus", "agreed": true, "close_date_time": "2021-10-26 11:35:46", "close_timestamp": 1637926546719, "created": "26/11/2021 11:35:48", "department": "Computing", "disability": true, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-11-26", "gender": "male", "id": "766ba3b6-bbbe-419d-b594-587006529f8a", "open_date_time": "2021-10-26 11:25:18", "open_timestamp": 1637925918816, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "Novavax has been doing a large scale in USA & Mexico, where results against the alpha variant have been around 93%. Other trial are taking place in South Africa and the UK. The trials are intended to lead to approval shortly and then made available in the USA and outside.", "task_condition": "text", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "post_graduate_phd", "time_taken_in_seconds": 627903, "what": "Drug trial & approval", "when_happened": "few_month_ago", "where_location": "USA, Mexico", "who": "Novavax/Vacine Developer, Serum Institute of India/Manufacturing Partner, Gavi/Manufacturing Partner, Global Data/Nancy Jaser/Phrama Analyst", "why": "It indicates the efficacy and availability of the Covid-19 drug"}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "GOLD_22 ", "age_group": "51_plus", "agreed": true, "close_date_time": "2021-10-26 11:55:15", "close_timestamp": 1637927715439, "created": "26/11/2021 11:55:15", "department": "Computing", "disability": true, "ease": 1, "environment": "production", "experiment_date_datepicker": "2021-11-26", "gender": "male", "id": "3bf4163e-6080-40bb-961c-1ec5a2c867c8", "open_date_time": "2021-10-26 11:51:5", "open_timestamp": 1637927465849, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "Unvaccinated people are feeding therapy in Australia so GP's are being urged to use ivermectin as a therapy to fight Covid-19", "task_condition": "viz", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "post_graduate_phd", "time_taken_in_seconds": 249590, "what": "Drug, therapy, Covid-19, ivermectin", "when_happened": "few_years_ago", "where_location": "Australia", "who": "Australian GP", "why": "Therapy needed, unvaccinated people"}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "GOLD_22 ", "age_group": "51_plus", "agreed": true, "close_date_time": "2021-10-26 11:44:49", "close_timestamp": 1637927089850, "created": "26/11/2021 11:44:51", "department": "Computing", "disability": true, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-11-26", "gender": "male", "id": "5aa26123-11a3-4f78-bc00-c1ce786aa555", "open_date_time": "2021-10-26 11:36:6", "open_timestamp": 1637926566554, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "The Roche drug Ronapreve has been approved for use in Japan and elsewhere andwill be maufacured by Chugai Pharmaceutical", "task_condition": "text", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "post_graduate_phd", "time_taken_in_seconds": 523296, "what": "Ronapreve, Roche, approval, Japan, worldwide", "when_happened": "few_years_ago", "where_location": "Switzerland, Japan", "who": "Roche, Japan Ministry of Health, Labour & Welfare, Chug Pharmaceuticals, European Medicines Agency", "why": "A new treatment for Covide-19 is available and seems effective against various varieties."}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "GOLD_22 ", "age_group": "51_plus", "agreed": true, "close_date_time": "2021-10-26 12:5:44", "close_timestamp": 1637928344891, "created": "26/11/2021 12:05:46", "department": "Computing", "disability": true, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-26", "gender": "male", "id": "29e74a25-e3bb-4b4f-be38-c4c4cd6aa83e", "open_date_time": "2021-10-26 11:55:21", "open_timestamp": 1637927721078, "summary": "Drugs need to go through regulatory approval processes, which is a rigorous and often lengthy process. This is illustrated in the cases of various drugs such as Myfembree. The Covid-19 pandemic required swift response. This led to accelerated approval process, manufacturing agreements and profits for the drug companies. \r\n\r\nAs part of the process for approval of Covid-19 vaccines, trails were conducted on various demographics, including specific interventions and approval submissions for treatments for children and for teenagers.\r\n\r\nThe industry is complex but has a number of large companies such as Pfizer who develop their own treatments but also buy up companies who have been developing innovative specialised approaches.", "task_condition": "text", "task_key": "pfizer", "task_level": "post_graduate_phd", "time_taken_in_seconds": 623813}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "GOLD_22 ", "age_group": "51_plus", "agreed": true, "close_date_time": "2021-10-26 12:18:56", "close_timestamp": 1637929136261, "created": "26/11/2021 12:18:57", "department": "Computing", "disability": true, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-26", "gender": "male", "id": "b71d5fda-afcd-43f3-bea1-b3a7423ee094", "open_date_time": "2021-10-26 12:5:54", "open_timestamp": 1637928354545, "summary": "The Swedish/UK firm AstraZeneca is involved in a variety of treatments for various conditions, including Covid-19, lung cancer and asthma. The common link is respiratory conditions. \r\n\r\nAn issue which caused a lot of fuss, particular with the EU drug regulating authorities, concerning AstraZeneca's Covid-19 treatment was the very are incidence of blood clots in some patients. A recommendation was made to add it asa list of possible side effects.\r\n\r\nAstraZeneca periodically buy companies that would add to its research or treatment portfolio, but these transactions can be flagged as affecting competition in the industry so at times are investigated or blocked by industry regulators.", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "post_graduate_phd", "time_taken_in_seconds": 781716}}}